John Franklin Enders received the 1954 Nobel Prize in Physiology or Medicine "for their discovery of the ability of polioviruses to grow in cultures of various types of tissue". Meanwhile, Jonas Salk applied the Enders-Weller-Robbins technique to produce large quantities of poliovirus, and then developed a polio vaccine in 1952. Upon the 1954 polio vaccine field trial, whose success Salk announced on the radio, Salk became a public hero but failed to credit the many other researchers that his effort rode upon, and was somewhat shunned by America's scientific establishment. In 1954, Enders and Peebles isolated measlesvirus from an 11-year-old boy, David Edmonston.
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood